CLINICAL TRIAL SUMMARY

MDACC Study No:2010-0187 (clinicaltrials.gov NCT No: NCT01191749)
Title:PHASE II PILOT STUDY OF ALEMTUZUMAB IN PATIENTS WITH LOW OR INT - 1 RISK MEYLODYSPLASTIC SYNDROME (MDS), APLASTIC ANEMIA (AA), OR T - CELL LARGE GRANULAR LYMPHOCYTIC LEUKEMIA (T - LGL)
Principal Investigator:Tapan Kadia
Treatment Agent:Campath-1H
Study Status:Terminated
Study Description:The goal of this clinical research study is to determine the effectiveness of
alemtuzumab in patients with aplastic anemia, MDS, or T-Cell large granular
lymphocytic leukemia. The safety of alemtuzumab will also be studied.

Hide details for General InformationGeneral Information

Disease Group:Hematologic Disorder; Leukemia
Phase of Study:Phase II
Treatment Agents:Campath-1H
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:
Supported By:N/A
Return Visit:
Home Care:


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Tapan Kadia
Dept:Leukemia
For Clinical Trial Enrollment:713-563-3534
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults